Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per share from the same period last year.